Identification

Name
Olopatadine
Accession Number
DB00768  (APRD00310)
Type
Small Molecule
Groups
Approved
Description

Used to treat allergic conjunctivitis (itching eyes), olopatadine inhibits the release of histamine from mast cells. It is a relatively selective histamine H1 antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells.

Structure
Thumb
Synonyms
  • Olopatadin
  • Olopatadina
  • Olopatadine
  • Olopatadinum
  • Opatanol
External IDs
AL-4943A / ALO 4943 A / KW 4679
Product Ingredients
IngredientUNIICASInChI Key
Olopatadine Hydrochloride2XG66W44KF140462-76-6HVRLZEKDTUEKQH-NOILCQHBSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Olopatadine 0.1%Solution0.1 %OphthalmicActavis Pharma Company2013-12-06Not applicableCanada
Act Olopatadine 0.2%Solution0.2 %OphthalmicActavis Pharma Company2014-02-20Not applicableCanada
Olopatadine Hydrochloride NasalSpray665 ug/1NasalPerrigo New York Inc.2015-04-012018-02-01Us
Olopatadine Ophthalmic SolutionSolution0.1 %OphthalmicBeximco Pharmaceuticals Canada LimitedNot applicableNot applicableCanada
PatadaySolution / drops2 mg/mLOphthalmicLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2012-04-032017-10-04Us
PatadaySolution / drops2 mg/mLOphthalmicAlcon, Inc.2007-02-15Not applicableUs
PatadaySolution / drops2 mg/mLOphthalmicPhysicians Total Care, Inc.2011-01-03Not applicableUs
PatadaySolution0.2 %OphthalmicNovartis2011-04-14Not applicableCanada
PatanaseSpray, metered665 ug/1NasalClinical Solutions Wholsesale2008-04-282017-07-01Us
PatanaseSpray, metered600 ug/1NasalAlcon, Inc.2008-04-28Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-olopatadineSolution0.2 %OphthalmicApotex Corporation2014-04-10Not applicableCanada
Apo-olopatadineSolution0.1 %OphthalmicApotex Corporation2013-07-26Not applicableCanada
Jamp-olopatadineSolution0.1 %OphthalmicJamp Pharma Corporation2017-10-06Not applicableCanada
Mint-olopatadineSolution0.1 %OphthalmicMint Pharmaceuticals Inc2014-07-29Not applicableCanada
OlopatadineSolution / drops2 mg/mLOphthalmicA S Medication Solutions2017-12-05Not applicableUs
OlopatadineSolution / drops2 mg/mLOphthalmicAkorn2017-12-05Not applicableUs
OlopatadineSolution / drops1 mg/mLOphthalmicAkorn2017-01-10Not applicableUs
OlopatadineSolution / drops1 mg/mLOphthalmicGolden State Medical Supply2018-01-08Not applicableUs
Olopatadine HydrochlorideSolution / drops1.11 mg/mLOphthalmicNovel Laboratories, Inc.2015-12-072016-10-13Us
Olopatadine HydrochlorideSolution / drops1.11 mg/mLOphthalmicSomerset Therapeutics, Llc2016-06-29Not applicableUs
International/Other Brands
Alchek (Apex) / Alerchek (Indoco) / Allelock (Dae Woong) / Opatanol (Alcon) / Patanol S (Alcon)
Categories
UNII
D27V6190PM
CAS number
113806-05-6
Weight
Average: 337.4122
Monoisotopic: 337.167793607
Chemical Formula
C21H23NO3
InChI Key
JBIMVDZLSHOPLA-LSCVHKIXSA-N
InChI
InChI=1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8-
IUPAC Name
2-[(2Z)-2-[3-(dimethylamino)propylidene]-9-oxatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3(8),4,6,11,13-hexaen-5-yl]acetic acid
SMILES
CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2

Pharmacology

Indication

For the treatment of ocular itching associated with allergic conjunctivitis.

Associated Conditions
Pharmacodynamics

Used to treat allergic conjunctivitis (itching eyes), olopatadine inhibits the release of histamine from mast cells. It is a relatively selective histamine H1 antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells.

Mechanism of action

Olopatadine is a selective histamine H1 antagonist that binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Olopatadine is devoid of effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Human
UProtein S100-A1
antagonist
Human
UProtein S100-A12
antagonist
Human
UProtein S100-B
other/unknown
Human
UProtein S100-A13
other/unknown
Human
UProtein S100-A2
antagonist
Human
Absorption

Ophthalmic use of olopatadine usually does not produce measurable plasma concentrations.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

The mono-desmethyl and the N-oxide metabolites have been detected at low concentrations in the urine.

Route of elimination

Elimination was predominantly through renal excretion.

Half life

3 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Olopatadine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when Olopatadine is combined with (4R)-limonene.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Olopatadine is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Olopatadine is combined with 19-norandrostenedione.Experimental, Illicit
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Olopatadine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Olopatadine.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Olopatadine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Olopatadine.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Olopatadine is combined with 5-androstenedione.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Olopatadine is combined with 7-Nitroindazole.Experimental
AbciximabOlopatadine may increase the anticoagulant activities of Abciximab.Approved
AcebutololOlopatadine may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Olopatadine is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolOlopatadine may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Aceprometazine.Approved
Acetyl sulfisoxazoleThe metabolism of Olopatadine can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Olopatadine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Olopatadine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Alaproclate.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Olopatadine is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Alendronic acid.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Olopatadine.Approved, Illicit
AliskirenOlopatadine may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Allopregnanolone.Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Alminoprofen.Experimental
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Olopatadine.Approved, Illicit, Investigational
AlprenololOlopatadine may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Olopatadine.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Amcinonide.Approved
AmikacinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Amikacin.Approved, Investigational, Vet Approved
AmilorideOlopatadine may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Aminosalicylic Acid.Approved
AmiodaroneThe risk or severity of QTc prolongation can be increased when Olopatadine is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Olopatadine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Olopatadine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Olopatadine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Amperozide.Experimental
AmphetamineAmphetamine may decrease the sedative activities of Olopatadine.Approved, Illicit, Investigational
AncrodOlopatadine may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Olopatadine is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Olopatadine is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Antipyrine.Approved, Investigational
Antithrombin III humanOlopatadine may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Antrafenine.Approved
ApalutamideThe serum concentration of Olopatadine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanOlopatadine may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Olopatadine is combined with Apocynin.Investigational
ApramycinOlopatadine may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Olopatadine is combined with Apremilast.Approved, Investigational
AprepitantThe serum concentration of Olopatadine can be increased when it is combined with Aprepitant.Approved, Investigational
ArbekacinOlopatadine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinOlopatadine may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanOlopatadine may increase the anticoagulant activities of Argatroban.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Olopatadine.Approved, Investigational
ArotinololOlopatadine may decrease the antihypertensive activities of Arotinolol.Investigational
ArticaineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Olopatadine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Atamestane.Investigational
AtazanavirThe metabolism of Olopatadine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololOlopatadine may decrease the antihypertensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Olopatadine can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Azaperone.Investigational, Vet Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Azapropazone.Withdrawn
AzelastineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Olopatadine is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Olopatadine.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Olopatadine.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Olopatadine.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Balsalazide.Approved, Investigational
BarbitalThe risk or severity of adverse effects can be increased when Olopatadine is combined with Barbital.Illicit
BecaplerminOlopatadine may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BefunololOlopatadine may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinOlopatadine may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Olopatadine is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Olopatadine is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Olopatadine.Approved
BenorilateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Benoxaprofen.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Benperidol.Approved, Investigational
BenzatropineThe risk or severity of QTc prolongation can be increased when Benzatropine is combined with Olopatadine.Approved
BenzphetamineBenzphetamine may decrease the sedative and stimulatory activities of Olopatadine.Approved, Illicit
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Olopatadine.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Benzydamine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Olopatadine is combined with Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineOlopatadine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Olopatadine is combined with Bepridil.Approved, Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Olopatadine.Investigational
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Olopatadine.Approved, Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Betamethasone.Approved, Vet Approved
BetaxololOlopatadine may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Olopatadine.Approved, Investigational
BevantololOlopatadine may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Olopatadine is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Olopatadine.Approved, Investigational
BisoprololOlopatadine may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinOlopatadine may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Olopatadine can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololOlopatadine may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Olopatadine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Olopatadine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Olopatadine is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Olopatadine.Approved, Illicit, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Olopatadine is combined with Bromfenac.Approved
BromisovalThe risk or severity of adverse effects can be increased when Olopatadine is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Brotizolam.Approved, Investigational, Withdrawn
BucillamineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Bucillamine.Investigational
BucindololOlopatadine may decrease the antihypertensive activities of Bucindolol.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Olopatadine is combined with Bufexamac.Approved, Experimental
BufuralolOlopatadine may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Olopatadine.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Bupivacaine.Approved, Investigational
BupranololOlopatadine may decrease the antihypertensive activities of Bupranolol.Approved
BuprenorphineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Olopatadine is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Olopatadine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Olopatadine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Olopatadine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Olopatadine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Olopatadine.Approved, Illicit, Vet Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Olopatadine.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Olopatadine.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Olopatadine is combined with Candoxatril.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Olopatadine is combined with Canertinib.Investigational
CapsaicinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Olopatadine is combined with Captopril.Approved
CarbamazepineThe metabolism of Olopatadine can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Olopatadine is combined with Carbaspirin calcium.Experimental, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Olopatadine.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Olopatadine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Olopatadine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Olopatadine.Approved
CarprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololOlopatadine may decrease the antihypertensive activities of Carteolol.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Olopatadine is combined with Celecoxib.Approved, Investigational
CeliprololOlopatadine may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Olopatadine can be increased when it is combined with Ceritinib.Approved
CertoparinOlopatadine may increase the anticoagulant activities of Certoparin.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Olopatadine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Olopatadine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Chloroprocaine.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Olopatadine.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Olopatadine.Approved, Vet Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Olopatadine is combined with Chlorphenamine.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorphentermineChlorphentermine may decrease the sedative activities of Olopatadine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Olopatadine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Olopatadine.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Olopatadine.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Olopatadine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Olopatadine is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Olopatadine is combined with Cimicoxib.Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Cinchocaine.Approved, Vet Approved
CinnarizineThe risk or severity of QTc prolongation can be increased when Olopatadine is combined with Cinnarizine.Approved, Investigational
CinoxacinOlopatadine may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Olopatadine is combined with Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Cisplatin.Approved
CitalopramThe risk or severity of adverse effects can be increased when Olopatadine is combined with Citalopram.Approved
ClarithromycinThe metabolism of Olopatadine can be decreased when combined with Clarithromycin.Approved
ClemastineThe risk or severity of QTc prolongation can be increased when Olopatadine is combined with Clemastine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clidinium.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clindamycin.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Olopatadine.Approved, Illicit
ClobetasolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clodronic Acid.Approved, Investigational, Vet Approved
clomethiazoleThe risk or severity of adverse effects can be increased when Olopatadine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Olopatadine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clonixin.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clopenthixol.Experimental
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Olopatadine.Vet Approved
CloranololOlopatadine may decrease the antihypertensive activities of Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Olopatadine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Olopatadine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Olopatadine.Approved
CobicistatThe metabolism of Olopatadine can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Olopatadine.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Olopatadine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Olopatadine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Olopatadine.Approved, Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Cortisone acetate.Approved, Investigational
CrizotinibThe metabolism of Olopatadine can be decreased when combined with Crizotinib.Approved
CurcuminThe metabolism of Olopatadine can be decreased when combined with Curcumin.Approved, Investigational
CyclizineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Olopatadine.Approved
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Olopatadine.Experimental
CyclopropaneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Cyclopropane.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Olopatadine.Approved
Dabigatran etexilateOlopatadine may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Olopatadine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DalteparinOlopatadine may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidOlopatadine may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DantroleneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dapoxetine.Investigational
DarexabanOlopatadine may increase the anticoagulant activities of Darexaban.Investigational
DarunavirThe metabolism of Olopatadine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Olopatadine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Olopatadine can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Olopatadine is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Olopatadine is combined with Delapril.Investigational
DelavirdineThe metabolism of Olopatadine can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Olopatadine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desipramine.Approved, Investigational
DesirudinOlopatadine may increase the anticoagulant activities of Desirudin.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Olopatadine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dexamethasone isonicotinate.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Olopatadine.Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Olopatadine.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dexmedetomidine.Approved, Vet Approved
DextranOlopatadine may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Olopatadine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Olopatadine.Approved, Illicit, Investigational, Vet Approved
DibekacinOlopatadine may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dibotermin alfa.Approved, Investigational
DicoumarolOlopatadine may increase the anticoagulant activities of Dicoumarol.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Olopatadine is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may decrease the sedative and stimulatory activities of Olopatadine.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Difenoxin.Approved, Illicit
DifenpiramideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Olopatadine is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Olopatadine.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Olopatadine.Approved, Illicit
DihydroergotamineThe metabolism of Olopatadine can be decreased when combined with Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinOlopatadine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemThe metabolism of Olopatadine can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Olopatadine is combined with Dimenhydrinate.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Olopatadine.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Olopatadine.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Olopatadine.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Olopatadine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Olopatadine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Doramectin.Vet Approved
DotarizineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dotarizine.Investigational
DoxepinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Doxepin.Approved, Investigational
DoxycyclineThe metabolism of Olopatadine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Olopatadine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved, Illicit
DronedaroneThe metabolism of Olopatadine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved, Vet Approved
DrospirenoneOlopatadine may increase the hyperkalemic activities of Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Drotebanol.Experimental, Illicit
DroxicamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Droxicam.Withdrawn
DuloxetineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Olopatadine is combined with Duvelisib.Investigational
DyclonineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dyclonine.Approved
E-6201The risk or severity of adverse effects can be increased when Olopatadine is combined with E-6201.Investigational
EcgonineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ecopipam.Investigational
Edetic AcidOlopatadine may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanOlopatadine may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Olopatadine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Eltanolone.Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Olopatadine is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Olopatadine is combined with Enalaprilat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Enflurane.Approved, Investigational, Vet Approved
EnoxacinOlopatadine may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinOlopatadine may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Olopatadine.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Olopatadine.Approved, Investigational
EnzalutamideThe serum concentration of Olopatadine can be decreased when it is combined with Enzalutamide.Approved
EpanololOlopatadine may decrease the antihypertensive activities of Epanolol.Experimental
EperisoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Eperisone.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Olopatadine is combined with Epirizole.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Olopatadine.Experimental
EplerenoneOlopatadine may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Olopatadine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Olopatadine.Approved
EquileninThe risk or severity of adverse effects can be increased when Olopatadine is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Equilin.Approved
ErythromycinThe metabolism of Olopatadine can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololOlopatadine may decrease the antihypertensive activities of Esatenolol.Experimental
EscitalopramThe risk or severity of adverse effects can be increased when Olopatadine is combined with Escitalopram.Approved, Investigational
EsmololOlopatadine may decrease the antihypertensive activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Olopatadine.Approved, Illicit
EstroneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Estrone sulfate.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Olopatadine.Approved, Investigational
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Olopatadine.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etanercept.Approved, Investigational
EthanolOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthenzamideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ethenzamide.Experimental
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Olopatadine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Olopatadine.Approved
Ethyl biscoumacetateOlopatadine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etidocaine.Approved
Etidronic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etidronic acid.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etizolam.Approved
EtodolacThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etofenamate.Approved, Investigational
EtomidateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etoperidone.Withdrawn
EtoricoxibThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etorphine.Illicit, Vet Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Olopatadine is combined with Evening primrose oil.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Olopatadine is combined with Exisulind.Investigational
EzogabineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ezogabine.Approved, Investigational
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Olopatadine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Felbamate.Approved
FelbinacThe risk or severity of adverse effects can be increased when Olopatadine is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fenbufen.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Olopatadine.Vet Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Olopatadine.Approved, Illicit, Investigational, Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Feprazone.Experimental
Ferulic acidOlopatadine may increase the anticoagulant activities of Ferulic acid.Experimental
FexofenadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fexofenadine.Approved, Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Olopatadine.Approved, Investigational
FleroxacinOlopatadine may increase the neuroexcitatory activities of Fleroxacin.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flibanserin.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Olopatadine.Approved, Withdrawn
FluanisoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluanisone.Experimental
FluasteroneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluasterone.Investigational
FluconazoleThe metabolism of Olopatadine can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fludiazepam.Approved, Illicit
FludrocortisoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fludrocortisone.Approved, Investigational
FluindioneOlopatadine may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineOlopatadine may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flumethasone.Approved, Vet Approved
FlunarizineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flunarizine.Approved
FlunisolideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flunisolide.Approved, Investigational
FlunitrazepamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flunitrazepam.Approved, Illicit
FlunixinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluorometholone.Approved, Investigational
FluoxetineThe risk or severity of QTc prolongation can be increased when Olopatadine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Olopatadine.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Olopatadine.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Olopatadine.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flurandrenolide.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Olopatadine.Approved, Illicit, Investigational
FlurbiprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flurbiprofen.Approved, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluspirilene.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Olopatadine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Olopatadine.Approved, Nutraceutical, Vet Approved
FondaparinuxOlopatadine may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Olopatadine.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Formestane.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Olopatadine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Olopatadine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Olopatadine can be increased when combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fospropofol.Approved, Illicit, Investigational
FramycetinOlopatadine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
Fusidic AcidThe serum concentration of Olopatadine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Olopatadine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Olopatadine is combined with Gabapentin Enacarbil.Approved, Investigational
GabexateOlopatadine may increase the anticoagulant activities of Gabexate.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Olopatadine.Approved, Illicit, Investigational
GarenoxacinOlopatadine may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinOlopatadine may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Olopatadine.Approved, Withdrawn
GemifloxacinOlopatadine may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinOlopatadine may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinOlopatadine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AOlopatadine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GepefrineGepefrine may decrease the sedative activities of Olopatadine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Olopatadine is combined with Gepirone.Investigational
GinsengThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ginseng.Approved, Investigational, Nutraceutical
GlutethimideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Glutethimide.Approved, Illicit
GrepafloxacinOlopatadine may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Olopatadine is combined with Guacetisal.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Halazepam.Approved, Illicit, Withdrawn
HalcinonideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Halothane.Approved, Vet Approved
HE3286The risk or severity of adverse effects can be increased when Olopatadine is combined with HE3286.Investigational
HeparinOlopatadine may increase the anticoagulant activities of Heparin.Approved, Investigational
HeroinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Olopatadine is combined with Hexobarbital.Approved
HigenamineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Higenamine.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Olopatadine.Approved, Investigational
HydralazineOlopatadine may decrease the antihypertensive activities of Hydralazine.Approved
HydrocodoneOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Olopatadine.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Olopatadine.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Olopatadine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved
Hygromycin BOlopatadine may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Olopatadine.Approved, Investigational
IbuproxamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Olopatadine is combined with Icatibant.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Olopatadine is combined with Icosapent.Approved, Nutraceutical
IdelalisibThe metabolism of Olopatadine can be decreased when combined with Idelalisib.Approved
IdraparinuxOlopatadine may increase the anticoagulant activities of Idraparinux.Investigational
IloperidoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Iloperidone.Approved
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Olopatadine.Approved, Investigational
ImatinibThe metabolism of Olopatadine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Olopatadine is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Imidazole salicylate.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Olopatadine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Indalpine.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Olopatadine.Approved
IndenololOlopatadine may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Olopatadine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Olopatadine is combined with Indiplon.Investigational
IndobufenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Indoprofen.Withdrawn
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Olopatadine.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Olopatadine.Approved, Investigational
IsavuconazoleThe serum concentration of Olopatadine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Olopatadine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsepamicinOlopatadine may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Olopatadine.Approved, Vet Approved
IsoxicamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Isoxicam.Withdrawn
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Olopatadine.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Olopatadine is combined with Istaroxime.Investigational
ItraconazoleThe metabolism of Olopatadine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Olopatadine can be increased when it is combined with Ivacaftor.Approved
KanamycinOlopatadine may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Kebuzone.Experimental
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Olopatadine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Olopatadine can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ketoprofen.Approved, Vet Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Olopatadine.Approved, Investigational
LandiololOlopatadine may decrease the antihypertensive activities of Landiolol.Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Olopatadine.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Leflunomide.Approved, Investigational
LepirudinOlopatadine may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanOlopatadine may increase the anticoagulant activities of Letaxaban.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Levetiracetam.Approved, Investigational
LevobetaxololOlopatadine may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololOlopatadine may decrease the antihypertensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Olopatadine is combined with Levodopa.Approved
LevofloxacinOlopatadine may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Olopatadine is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Olopatadine.Approved
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Olopatadine.Approved, Investigational
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Olopatadine.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Olopatadine is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Lisofylline.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Olopatadine.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Olopatadine is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Olopatadine can be increased when used in combination with Lofexidine.Approved, Investigational
LomefloxacinOlopatadine may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Olopatadine is combined with Lonazolac.Experimental
LopinavirThe metabolism of Olopatadine can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of QTc prolongation can be increased when Olopatadine is combined with Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Olopatadine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Lormetazepam.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Lornoxicam.Approved, Investigational
LorpiprazoleThe serum concentration of Olopatadine can be increased when it is combined with Lorpiprazole.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Loteprednol.Approved
LovastatinThe metabolism of Olopatadine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Olopatadine.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Olopatadine.Approved, Investigational
LuliconazoleThe serum concentration of Olopatadine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Olopatadine can be increased when combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Olopatadine is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Olopatadine.Vet Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Olopatadine.Approved, Investigational
Magnesium carbonateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Magnesium citrate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium salicylateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Magnesium salicylate.Approved
Magnesium sulfateThe therapeutic efficacy of Olopatadine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Magnesium Trisilicate.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Maprotiline.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Olopatadine.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Olopatadine is combined with ME-609.Investigational
MebicarThe risk or severity of adverse effects can be increased when Olopatadine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Olopatadine.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Meclofenamic acid.Approved, Vet Approved
MedazepamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Medetomidine.Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Mefenamic acid.Approved
MelagatranOlopatadine may increase the anticoagulant activities of Melagatran.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Olopatadine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelengestrolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Meloxicam.Approved, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Melperone.Approved, Investigational
MephedroneMephedrone may decrease the sedative activities of Olopatadine.Investigational
MephentermineMephentermine may decrease the sedative activities of Olopatadine.Approved
MepindololOlopatadine may decrease the antihypertensive activities of Mepindolol.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Olopatadine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Meptazinol.Experimental
MepyramineThe risk or severity of QTc prolongation can be increased when Mepyramine is combined with Olopatadine.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Mesalazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Mesoridazine.Approved, Investigational
MetamizoleThe risk or severity of adverse effects can be increased when Olopatadine is combined with Metamizole.Approved, Investigational, Withdrawn
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Olopatadine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Olopatadine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may decrease the sedative activities of Olopatadine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Olopatadine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Olopatadine.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Olopatadine.Approved
MethotrimeprazineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Olopatadine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Methsuximide.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Olopatadine.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Olopatadine is combined with Methylphenobarbital.Approved
MetipranololOlopatadine may decrease the antihypertensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Olopatadine.Approved, Investigational
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Olopatadine.Approved
MetyrosineOlopatadine may increase the sedative activities of Metyrosine.Approved
MibefradilThe metabolism of Olopatadine can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Olopatadine can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MicronomicinOlopatadine may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Olopatadine.Approved, Illicit
MidomafetamineMidomafetamine may decrease the sedative activities of Olopatadine.Experimental, Illicit, Investigational
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Olopatadine.Approved, Experimental
MifepristoneThe serum concentration of Olopatadine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Olopatadine is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved, Investigational
MirtazapineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Olopatadine.Approved
MitotaneThe serum concentration of Olopatadine can be decreased when it is combined with Mitotane.Approved
MizoribineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Mizoribine.Investigational
MMDAMMDA may decrease the sedative activities of Olopatadine.Experimental, Illicit
MoexiprilThe risk or severity of adverse effects can be increased when Olopatadine is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Mofebutazone.Experimental
MolindoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Molindone.Approved
MometasoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Olopatadine.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Olopatadine.Approved, Investigational
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Olopatadine is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Olopatadine.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Mycophenolic acid.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Nabumetone.Approved
NadololOlopatadine may decrease the antihypertensive activities of Nadolol.Approved
NadroparinOlopatadine may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatOlopatadine may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Olopatadine.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Olopatadine.Approved
Nalidixic AcidOlopatadine may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Olopatadine is combined with NCX 1022.Investigational
NeamineOlopatadine may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololOlopatadine may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Olopatadine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Olopatadine can be decreased when combined with Nelfinavir.Approved
NemonoxacinOlopatadine may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Neomycin.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Olopatadine is combined with Nepafenac.Approved, Investigational
NetilmicinOlopatadine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NetupitantThe serum concentration of Olopatadine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Olopatadine can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Olopatadine can be decreased when combined with Nicardipine.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Niflumic Acid.Approved
NilotinibThe metabolism of Olopatadine can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Olopatadine.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Nitroaspirin.Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Olopatadine.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Nordazepam.Approved
NorfloxacinOlopatadine may increase the neuroexcitatory activities of Norfloxacin.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Olopatadine.Approved
OfloxacinOlopatadine may increase the neuroexcitatory activities of Ofloxacin.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Olopatadine.Approved, Investigational
OlaparibThe metabolism of Olopatadine can be decreased when combined with Olaparib.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Olopatadine.Approved, Investigational
OlsalazineOlopatadine may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Olopatadine is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Olopatadine is combined with Omapatrilat.Investigational
OndansetronThe risk or severity of QTc prolongation can be increased when Olopatadine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Olopatadine is combined with Opium.Approved, Illicit
OrgoteinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Orgotein.Vet Approved
OrphenadrineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Olopatadine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Olopatadine can be increased when it is combined with Osimertinib.Approved
OtamixabanOlopatadine may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Oxaprozin.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Olopatadine.Approved
Oxolinic acidOlopatadine may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololOlopatadine may decrease the antihypertensive activities of Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Olopatadine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Olopatadine.Approved, Investigational, Vet Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Oxyphenbutazone.Approved, Withdrawn
PalbociclibThe serum concentration of Olopatadine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Olopatadine.Approved
PalmidrolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Palmidrol.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pamidronate.Approved
ParaldehydeOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Olopatadine is combined with Parecoxib.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Paroxetine.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Parthenolide.Approved, Investigational
PazufloxacinOlopatadine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinOlopatadine may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololOlopatadine may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Penfluridol.Experimental
Pentaerythritol TetranitrateOlopatadine may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Olopatadine.Approved, Vet Approved
PentobarbitalThe metabolism of Olopatadine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
Pentosan PolysulfateOlopatadine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved
PerazineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Perazine.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Olopatadine is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Olopatadine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Olopatadine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Olopatadine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Olopatadine is combined with Phenibut.Experimental
PhenindioneOlopatadine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniramineThe risk or severity of QTc prolongation can be increased when Olopatadine is combined with Pheniramine.Approved
PhenobarbitalThe metabolism of Olopatadine can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Phenoxyethanol.Approved
PhenprocoumonOlopatadine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenterminePhentermine may decrease the sedative activities of Olopatadine.Approved, Illicit
PhenylbutazoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Olopatadine can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Olopatadine.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Olopatadine.Approved
PindololOlopatadine may decrease the antihypertensive activities of Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pipamperone.Approved, Investigational
Pipemidic acidOlopatadine may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PipotiazineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pipotiazine.Approved, Investigational
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Olopatadine.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pirfenidone.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Piritramide.Approved, Investigational
Piromidic acidOlopatadine may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pirprofen.Experimental
PitolisantThe serum concentration of Olopatadine can be decreased when it is combined with Pitolisant.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pizotifen.Approved
Platelet Activating FactorOlopatadine may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinOlopatadine may decrease the excretion rate of Plazomicin which could result in a higher serum level.Approved, Investigational
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Polymyxin B Sulfate.Approved, Vet Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Olopatadine.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Olopatadine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium CitrateOlopatadine may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololOlopatadine may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Olopatadine.Approved, Investigational
PramipexoleOlopatadine may increase the sedative activities of Pramipexole.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Prasterone sulfate.Investigational
PrazepamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Prazepam.Approved, Illicit
PrednicarbateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Prednicarbate.Approved, Investigational
PrednisoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Prednisone.Approved, Vet Approved
PregabalinThe therapeutic efficacy of Olopatadine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PregnenoloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pregnenolone.Approved, Experimental, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Prilocaine.Approved
PrimidoneThe metabolism of Olopatadine can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Olopatadine can be increased when it is combined with Probenecid.Approved, Investigational
ProcaineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Olopatadine.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Proglumetacin.Experimental
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Olopatadine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Promethazine.Approved, Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Propacetamol.Approved, Investigational
PropafenoneThe risk or severity of QTc prolongation can be increased when Olopatadine is combined with Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Olopatadine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Olopatadine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Propoxycaine.Approved
PropyphenazoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Olopatadine.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Olopatadine.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Olopatadine.Vet Approved
Protein COlopatadine may increase the anticoagulant activities of Protein C.Approved
Protein S humanOlopatadine may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeOlopatadine may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Olopatadine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Olopatadine is combined with Proxibarbal.Experimental
PrulifloxacinOlopatadine may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PSD502The risk or severity of adverse effects can be increased when Olopatadine is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative and stimulatory activities of Olopatadine.Approved
PTC299The risk or severity of adverse effects can be increased when Olopatadine is combined with PTC299.Investigational
PuromycinOlopatadine may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrantelThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pyrantel.Approved, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Olopatadine.Approved, Illicit
QuetiapineThe risk or severity of QTc prolongation can be increased when Olopatadine is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Olopatadine is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Olopatadine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ramipril.Approved
RanolazineThe metabolism of Olopatadine can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Olopatadine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Remoxipride.Approved, Withdrawn
RescinnamineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Olopatadine.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinOlopatadine may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinOlopatadine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RifabutinThe metabolism of Olopatadine can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Olopatadine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Olopatadine can be increased when combined with Rifapentine.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Risedronate.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Olopatadine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ritanserin.Investigational
RitobegronRitobegron may decrease the sedative activities of Olopatadine.Investigational
RivaroxabanOlopatadine may increase the anticoagulant activities of Rivaroxaban.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Olopatadine is combined with Rizatriptan.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Olopatadine is combined with Rofecoxib.Approved, Investigational, Withdrawn
RomifidineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Romifidine.Vet Approved
RopiniroleOlopatadine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ropivacaine.Approved
RosoxacinOlopatadine may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RotigotineOlopatadine may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Olopatadine can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Olopatadine.Approved
RufloxacinOlopatadine may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Olopatadine.Approved
SalbutamolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Olopatadine.Approved, Vet Approved
SalicylamideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Salicylamide.Approved
SalmeterolThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Olopatadine.Approved
SalsalateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Olopatadine.Experimental
SaquinavirThe metabolism of Olopatadine can be decreased when combined with Saquinavir.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Olopatadine.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Olopatadine.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Olopatadine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Olopatadine.Approved, Vet Approved
SeliciclibThe risk or severity of adverse effects can be increased when Olopatadine is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Olopatadine is combined with Semapimod.Investigational
SepranoloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Sepranolone.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Olopatadine is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Olopatadine is combined with Serrapeptase.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Olopatadine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Olopatadine.Approved, Vet Approved
SildenafilThe metabolism of Olopatadine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Olopatadine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Olopatadine can be increased when it is combined with Simeprevir.Approved
SisomicinOlopatadine may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinOlopatadine may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved
SotalolOlopatadine may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinOlopatadine may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Olopatadine is combined with Spirapril.Approved
SRT501The risk or severity of adverse effects can be increased when Olopatadine is combined with SRT501.Investigational
St. John's WortThe serum concentration of Olopatadine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Olopatadine can be increased when it is combined with Stiripentol.Approved
StreptomycinOlopatadine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Olopatadine.Approved, Investigational
SulfisoxazoleThe metabolism of Olopatadine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulodexideOlopatadine may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Sulpiride.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Olopatadine.Investigational
SultoprideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Olopatadine is combined with Sumatriptan.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Suprofen.Approved, Withdrawn
SuvorexantOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
SuxibuzoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Suxibuzone.Experimental
TacrolimusOlopatadine may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Olopatadine.Approved
TalinololOlopatadine may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Olopatadine.Approved
TandospironeThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tarenflurbil.Investigational
TasimelteonThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tasimelteon.Approved, Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Olopatadine.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Technetium Tc-99m medronate.Approved
TelaprevirThe metabolism of Olopatadine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Olopatadine can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Olopatadine.Approved, Investigational
TemafloxacinOlopatadine may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Olopatadine.Approved, Investigational
TemocaprilThe risk or severity of adverse effects can be increased when Olopatadine is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tepoxalin.Vet Approved
TerbutalineOlopatadine may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Teriflunomide.Approved
TerodilineThe risk or severity of QTc prolongation can be increased when Olopatadine is combined with Terodiline.Experimental
TertatololOlopatadine may decrease the antihypertensive activities of Tertatolol.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tetracaine.Approved, Vet Approved
TetracyclineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tetracycline.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tetrodotoxin.Investigational
ThalidomideOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Olopatadine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Olopatadine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Olopatadine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Olopatadine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tiagabine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tiapride.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tiaprofenic acid.Approved
TiclopidineThe metabolism of Olopatadine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tilidine.Experimental
Tiludronic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololOlopatadine may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tixocortol.Approved, Withdrawn
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Olopatadine.Approved, Investigational
TobramycinOlopatadine may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TocilizumabThe serum concentration of Olopatadine can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Olopatadine.Approved, Withdrawn
TolmetinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tolmetin.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Olopatadine.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Olopatadine.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Olopatadine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Olopatadine is combined with Trandolapril.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tranylcypromine.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Olopatadine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Trazodone.Approved, Investigational
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Olopatadine.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Triamcinolone.Approved, Vet Approved
TriamtereneOlopatadine may decrease the antihypertensive activities of Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Olopatadine.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tribenoside.Experimental
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Olopatadine.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Olopatadine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Triflupromazine.Approved, Vet Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Trimethadione.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Olopatadine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Olopatadine.Approved
TriptolideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Triptolide.Investigational
TrovafloxacinOlopatadine may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinOlopatadine may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Olopatadine.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Olopatadine is combined with Valdecoxib.Approved, Investigational, Withdrawn
Valproic AcidThe risk or severity of QTc prolongation can be increased when Olopatadine is combined with Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Olopatadine.Approved, Investigational
VancomycinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Vancomycin.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Olopatadine is combined with Vecuronium.Approved
VemurafenibThe serum concentration of Olopatadine can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Veralipride.Experimental
VerapamilThe metabolism of Olopatadine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Vigabatrin.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Olopatadine is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Olopatadine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Vortioxetine.Approved, Investigational
WarfarinOlopatadine may increase the anticoagulant activities of Warfarin.Approved
XenonThe risk or severity of adverse effects can be increased when Olopatadine is combined with Xenon.Experimental
XimelagatranOlopatadine may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
XylazineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Olopatadine.Approved, Illicit, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Zaltoprofen.Approved, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ziconotide.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Olopatadine.Approved, Investigational, Withdrawn
ZimelidineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Olopatadine can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe risk or severity of adverse effects can be increased when Olopatadine is combined with Zofenopril.Experimental
ZolazepamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Olopatadine is combined with Zolmitriptan.Approved, Investigational
ZolpidemOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Olopatadine is combined with Zomepirac.Withdrawn
ZonisamideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Olopatadine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Olopatadine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Thomas Bader, Hans-Ulrich Bichsel, Bruno Gilomen, Imelda Meyer-Wilmes, Mark Sundermeier, "Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof." U.S. Patent US20070232814, issued October 04, 2007.

US20070232814
General References
  1. Ohmori K, Hayashi K, Kaise T, Ohshima E, Kobayashi S, Yamazaki T, Mukouyama A: Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol. 2002 Apr;88(4):379-97. [PubMed:12046981]
  2. Yanni JM, Stephens DJ, Miller ST, Weimer LK, Graff G, Parnell D, Lang LS, Spellman JM, Brady MT, Gamache DA: The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther. 1996 Winter;12(4):389-400. [PubMed:8951675]
  3. Ohmori K, Hasegawa K, Tamura T, Miyake K, Matsubara M, Masaki S, Karasawa A, Urayama N, Horikoshi K, Kajita J, Hasegawa M, Taniguchi K, Komada T, Kawamoto Y: Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug. Arzneimittelforschung. 2004;54(12):809-29. [PubMed:15646365]
  4. Ohmori K, Ikemura T, Kobayashi H, Mukouyama A: [Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride' (olopatadine), an antiallergic drug]. Nihon Yakurigaku Zasshi. 2001 Jul;118(1):51-8. [PubMed:11496828]
  5. Kaliner MA, Oppenheimer J, Farrar JR: Comprehensive review of olopatadine: the molecule and its clinical entities. Allergy Asthma Proc. 2010 Mar-Apr;31(2):112-9. doi: 10.2500/aap.2010.31.3317. [PubMed:20406593]
External Links
Human Metabolome Database
HMDB0014906
KEGG Compound
C07789
PubChem Compound
5281071
PubChem Substance
46506025
ChemSpider
4444528
BindingDB
50002096
ChEMBL
CHEMBL1189432
Therapeutic Targets Database
DAP001062
PharmGKB
PA450698
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Olopatadine
ATC Codes
S01GX09 — OlopatadineR01AC08 — Olopatadine
AHFS Codes
  • 52:02.00 — Antiallergic Agents
  • 04:00.00 — Antihistamine Drugs
FDA label
Download (114 KB)
MSDS
Download (57.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableConjunctivitis, Seasonal Allergic1
2CompletedTreatmentConjunctivitis, Seasonal Allergic3
2TerminatedTreatmentSeasonal Allergic Conjunctivitis to Ragweed1
3Active Not RecruitingTreatmentRhinitis, Allergic, Seasonal1
3CompletedNot AvailableConjunctivitis, Seasonal Allergic2
3CompletedPreventionConjunctivitis, Seasonal Allergic1
3CompletedTreatmentConjunctivitis, Seasonal Allergic7
3CompletedTreatmentConjunctivitis, Seasonal Allergic / Rhinitis, Allergic, Seasonal1
3SuspendedTreatmentConjunctivitis, Seasonal Allergic1
4CompletedNot AvailableConjunctivitis, Seasonal Allergic1
4CompletedNot AvailableSeasonal Allergic Rhinitis (SAR)1
4CompletedDiagnosticConjunctivitis, Seasonal Allergic2
4CompletedPreventionConjunctivitis, Seasonal Allergic1
4CompletedTreatmentConjunctivitis, Seasonal Allergic10
4CompletedTreatmentPerennial Allergic Rhinitis (PAR)1
4RecruitingTreatmentConjunctivitis, Seasonal Allergic / Conjunctivitis, Vernal1
4WithdrawnTreatmentAllergic Rhinitis (AR)1
4WithdrawnTreatmentConjunctivitis, Seasonal Allergic1
Not AvailableCompletedTreatmentEye Allergies1
Not AvailableUnknown StatusBasic ScienceAllergic Eye Disease1

Pharmacoeconomics

Manufacturers
  • Alcon inc
  • Alcon laboratories inc
  • Alcon Laboratories, Inc.
Packagers
  • Alcon Laboratories
  • A-S Medication Solutions LLC
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Lake Erie Medical and Surgical Supply
  • Physicians Total Care Inc.
  • Redpharm Drug
Dosage forms
FormRouteStrength
SolutionOphthalmic0.1 %
SolutionOphthalmic0.2 %
SolutionOphthalmic2 mg/mL
Solution / dropsOphthalmic1 mg/mL
Solution / dropsOphthalmic1.11 mg/mL
Spray, meteredNasal665 ug/100uL
SprayNasal665 ug/1
Solution / dropsOphthalmic2 mg/mL
Spray, meteredNasal600 ug/1
Spray, meteredNasal665 ug/1
LiquidOphthalmic0.1 %
SolutionOphthalmic0.7 %
SolutionOphthalmic7 mg/mL
Prices
Unit descriptionCostUnit
Patanol 0.1% Solution 5ml Bottle111.2USD bottle
Pataday 0.2% eye drops52.98USD ml
Patanol 0.1% eye drops21.38USD ml
Patanase 0.6% nasal spray3.83USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5116863No1993-12-182010-12-18Us
CA2195094No2002-02-262016-05-03Canada
CA1337603No1995-11-212012-11-21Canada
US6995186Yes2004-05-122024-05-12Us
US7402609Yes2002-12-192022-12-19Us
US8399508Yes2003-03-172023-03-17Us
US7977376Yes2003-08-022023-08-02Us
US8791154No2012-05-192032-05-19Us
US5641805Yes1995-12-062015-12-06Us
US9533053No2012-05-192032-05-19Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)248 °CNot Available
water solubilitySolubleNot Available
logP3.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0313 mg/mLALOGPS
logP3.99ALOGPS
logP0.75ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)3.78ChemAxon
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area49.77 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity109.55 m3·mol-1ChemAxon
Polarizability37.44 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9747
Blood Brain Barrier+0.6925
Caco-2 permeable+0.7249
P-glycoprotein substrateSubstrate0.8607
P-glycoprotein inhibitor IInhibitor0.5948
P-glycoprotein inhibitor IINon-inhibitor0.8196
Renal organic cation transporterInhibitor0.5413
CYP450 2C9 substrateNon-substrate0.7691
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7242
CYP450 1A2 substrateInhibitor0.7906
CYP450 2C9 inhibitorNon-inhibitor0.8316
CYP450 2D6 inhibitorInhibitor0.6567
CYP450 2C19 inhibitorNon-inhibitor0.8466
CYP450 3A4 inhibitorNon-inhibitor0.8222
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8676
Ames testNon AMES toxic0.8032
CarcinogenicityNon-carcinogens0.8499
BiodegradationNot ready biodegradable0.6088
Rat acute toxicity2.7626 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8082
hERG inhibition (predictor II)Inhibitor0.5
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-0090000000-8e3ac3f01c9b0f33191f
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0007-0090000000-ff327751665292322357
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00ke-0190000000-4ee44c0a1808c8f38f5f
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014l-0490000000-af62db4d573fa623449b
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014l-0690000000-855734373da970ef9009
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014l-0970000000-10c3777ced99134b4960
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0009000000-edd957bf788fa0da1cd5
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0019000000-76019801740d70094185
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00kk-0593000000-0fb46422a259d1710df5
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-016s-0690000000-d2686bcc07833ec6a7c5
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0fw9-0690000000-20403692a9e2a6948063
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-0009000000-e2c029010aa3133274f8
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-1239000000-a4a1f419cb7782a025ae
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-015a-4890000000-5408d5e1274f9ec8ab42
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00lu-4970000000-5d3cad1a8e8d0b931c62
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00lu-4960000000-d57d90bc4e9b3f57c2fa
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0frx-5960000000-9b3e25cd1765878b5709
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-0469000000-a0b3c5cdd43e637acdec

Taxonomy

Description
This compound belongs to the class of organic compounds known as dibenzoxepines. These are compounds containing a dibenzoxepine moiety, which consists of two benzene connected by an oxazepine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzoxepines
Sub Class
Dibenzoxepines
Direct Parent
Dibenzoxepines
Alternative Parents
Alkyl aryl ethers / Benzenoids / Trialkylamines / Amino acids / Oxacyclic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
show 1 more
Substituents
Dibenzoxepine / Alkyl aryl ether / Benzenoid / Amino acid or derivatives / Amino acid / Tertiary aliphatic amine / Tertiary amine / Carboxylic acid derivative / Carboxylic acid / Oxacycle
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Tamura T, Masaki S, Ohmori K, Karasawa A: Effect of olopatadine and other histamine H1 receptor antagonists on the skin inflammation induced by repeated topical application of oxazolone in mice. Pharmacology. 2005 Dec;75(1):45-52. Epub 2005 Jun 7. [PubMed:15942272]
  2. Ohmori K, Hayashi K, Kaise T, Ohshima E, Kobayashi S, Yamazaki T, Mukouyama A: Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol. 2002 Apr;88(4):379-97. [PubMed:12046981]
  3. Yanni JM, Stephens DJ, Miller ST, Weimer LK, Graff G, Parnell D, Lang LS, Spellman JM, Brady MT, Gamache DA: The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther. 1996 Winter;12(4):389-400. [PubMed:8951675]
  4. Ohmori K, Hasegawa K, Tamura T, Miyake K, Matsubara M, Masaki S, Karasawa A, Urayama N, Horikoshi K, Kajita J, Hasegawa M, Taniguchi K, Komada T, Kawamoto Y: Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug. Arzneimittelforschung. 2004;54(12):809-29. [PubMed:15646365]
  5. Ohmori K, Ikemura T, Kobayashi H, Mukouyama A: [Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride' (olopatadine), an antiallergic drug]. Nihon Yakurigaku Zasshi. 2001 Jul;118(1):51-8. [PubMed:11496828]
  6. Roland PS, Ryan MW, Wall GM: Olopatadine nasal spray for the treatment of seasonal allergic rhinitis in patients aged 6 years and older. Expert Opin Pharmacother. 2010 Jun;11(9):1559-67. doi: 10.1517/14656566.2010.485609. [PubMed:20482305]
  7. Kaliner MA, Oppenheimer J, Farrar JR: Comprehensive review of olopatadine: the molecule and its clinical entities. Allergy Asthma Proc. 2010 Mar-Apr;31(2):112-9. doi: 10.2500/aap.2010.31.3317. [PubMed:20406593]
  8. Roland PS, Marple BF, Wall GM: Olopatadine nasal spray for the treatment of allergic rhinitis. Expert Rev Clin Immunol. 2010 Mar;6(2):197-204. [PubMed:20402382]
  9. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
S100 protein binding
Specific Function
Weakly binds calcium but binds zinc very tightly-distinct binding sites with different affinities exist for both ions on each monomer. Physiological concentrations of potassium ion antagonize the b...
Gene Name
S100A1
Uniprot ID
P23297
Uniprot Name
Protein S100-A1
Molecular Weight
10545.755 Da
References
  1. Okada M, Tokumitsu H, Kubota Y, Kobayashi R: Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. Biochem Biophys Res Commun. 2002 Apr 12;292(4):1023-30. [PubMed:11944917]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Zinc ion binding
Specific Function
S100A12 is a calcium-, zinc- and copper-binding protein which plays a prominent role in the regulation of inflammatory processes and immune response. Its proinflammatory activity involves recruitme...
Gene Name
S100A12
Uniprot ID
P80511
Uniprot Name
Protein S100-A12
Molecular Weight
10574.975 Da
References
  1. Kishimoto K, Kaneko S, Ohmori K, Tamura T, Hasegawa K: Olopatadine suppresses the migration of THP-1 monocytes induced by S100A12 protein. Mediators Inflamm. 2006;2006(1):42726. [PubMed:16864903]
  2. Okada M, Tokumitsu H, Kubota Y, Kobayashi R: Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. Biochem Biophys Res Commun. 2002 Apr 12;292(4):1023-30. [PubMed:11944917]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Zinc ion binding
Specific Function
Weakly binds calcium but binds zinc very tightly-distinct binding sites with different affinities exist for both ions on each monomer. Physiological concentrations of potassium ion antagonize the b...
Gene Name
S100B
Uniprot ID
P04271
Uniprot Name
Protein S100-B
Molecular Weight
10712.985 Da
References
  1. Okada M, Tokumitsu H, Kubota Y, Kobayashi R: Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. Biochem Biophys Res Commun. 2002 Apr 12;292(4):1023-30. [PubMed:11944917]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Zinc ion binding
Specific Function
Plays a role in the export of proteins that lack a signal peptide and are secreted by an alternative pathway. Binds two calcium ions per subunit. Binds one copper ion. Binding of one copper ion doe...
Gene Name
S100A13
Uniprot ID
Q99584
Uniprot Name
Protein S100-A13
Molecular Weight
11471.095 Da
References
  1. Okada M, Tokumitsu H, Kubota Y, Kobayashi R: Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. Biochem Biophys Res Commun. 2002 Apr 12;292(4):1023-30. [PubMed:11944917]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Identical protein binding
Specific Function
May function as calcium sensor and modulator, contributing to cellular calcium signaling. May function by interacting with other proteins, such as TPR-containing proteins, and indirectly play a rol...
Gene Name
S100A2
Uniprot ID
P29034
Uniprot Name
Protein S100-A2
Molecular Weight
11116.695 Da
References
  1. Okada M, Tokumitsu H, Kubota Y, Kobayashi R: Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. Biochem Biophys Res Commun. 2002 Apr 12;292(4):1023-30. [PubMed:11944917]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 07:25